Table 2.
Univariable and multivariable overall survival analysis in patients with LUAD and LUSC.
| Univariable analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|
| n | HR (95% CI) | p | HR (95% CI) | p | |
| Characteristics (LUAD) | |||||
| Gender | |||||
| Male | 184 | 1.000 | \ | ||
| Female | 122 | 0.826 (0.621-1.098) | 0.188 | \ | \ |
| Age | |||||
| ≤60 | 146 | 1.000 | 1.000 | ||
| >60 | 160 | 1.665 (0.927-2.354) | 0.035 | 1.325 (0.815-1.968) | 0.041 |
| TNM stages | |||||
| I+II | 176 | 1.000 | 1.000 | ||
| III+IV | 130 | 2.167 (1.639-2.865) | <0.001 | 1.823 (1.151-2.887) | 0.010 |
| PCK1 pS90 | |||||
| Low | 118 | 1.000 | \ | ||
| High | 188 | 1.649 (1.223-2.223) | 0.001 | \ | \ |
| INSIG1 pS207/INSIG2 pS151 | |||||
| Low | 175 | 1.000 | \ | ||
| High | 131 | 1.555 (1.164-2.076) | 0.003 | \ | \ |
| PCK1 pS90+ INSIG1 pS207/INSIG2 pS151 | |||||
| Low | 142 | 1.000 | 1.000 | ||
| High | 164 | 1.996 (1.496-2.663) | <0.001 | 1.365 (0.777-2.154) | 0.040 |
| Characteristics (LUSC) | |||||
| Gender | |||||
| Male | 136 | 1.000 | \ | ||
| Female | 9 | 0.868 (0.418-1.804) | 0.703 | \ | \ |
| Age | |||||
| ≤60 | 47 | 1.000 | 1.000 | ||
| >60 | 98 | 1.312 (0.895-1.945) | 0.037 | 1.215 (0.758-1.856) | 0.043 |
| TNM stages | |||||
| I+II | 95 | 1.000 | 1.000 | ||
| III+IV | 50 | 7.493 (4.627-12.132) | <0.001 | 5.630 (3.084-10.277) | <0.001 |
| PCK1 pS90 | |||||
| Low | 1.000 | \ | |||
| High | 2.917 (1.902-4.473) | <0.001 | \ | \ | |
| INSIG1 pS207/INSIG2 pS151 | |||||
| Low | 1.000 | \ | |||
| High | 3.129 (2.014-4.861) | <0.001 | \ | \ | |
| PCK1 pS90+ INSIG1 pS207/INSIG2 pS151 | |||||
| Low | 1.000 | 1.000 | |||
| High | 3.405 (2.215-5.232) | <0.001 | 1.443 (0.935-2.156) | 0.033 | |
PCK1, Phosphoenolpyruvate (PEP) carboxykinase 1; LUAD, Lung adenocarcinoma; LUSC, Lung squamous cell carcinoma; INSIG, Insulin induced gene; IHC, Immunohistochemistry; HR, hazard ratio; 95% CI, 95% confidence interval. Bold values means the comparison results are significant.